Big Picture – A Deep Dive Examination of MaxCyte
History Driven by Scientific Advancements
We have pioneered the development of a cell-engineering platform based on Flow Electroporation™ Technology. Originally conceived to meet the stringent demands of cell therapy applications – namely the ability to safely and reproducibly modify human cells with high efficiency, low cytotoxicity and at the scale required to treat patients – we have expanded the platform and applications to accelerate the development of small molecule drugs, biologics and vaccines in addition to enhancing cell therapy applications.
Invented at the CBR Institute for Biomedical Research in Boston, Massachusetts, Flow Electroporation Technology was initially intended for the clinical treatment of ischemic disorders by loading an autologous red blood cell suspension with an alternative hemoglobin oxygen modulator. While the company was founded in 1999 to commercialize this technology, our scientists have since greatly expanded on this capability to load a wide range of biologically active molecules into a variety of cell types to enable many clinical and commercial applications.
In 2000, we developed the MaxCyte GT® Scalable Transfection System for cell therapy development and commercialization. In 2003, we began entering partnered license agreements with developers of human cell therapies to enable the development of novel therapeutic products based on our delivery platform. With the launch of the MaxCyte STX® Scalable Transfection System, the powerful platform was opened to the burgeoning areas of cell-based assays for high throughput and high content screening and preclinical protein production, greatly enhancing the speed and productivity in these fields.
Most recently our delivery platform has been employed in the exciting and growing fields of immuno-oncology and gene editing. With the announcement of our CARMA approach to RNA-based CAR-T driven therapies in 2015, we have taken our technology to the forefront of medicine by harnessing patients’ own immune systems to combat diseases, such as solid and liquid cancers.https://www.maxcyte.com/products-services/
MaxCyte has developed a novel and proprietary platform for next-generation chimeric antigen receptor (CAR)-engineered T/NK-cell therapies. Our CAR platform provides several unique attributes versus existing autologous CAR-T products and platforms. To read more click here.
Products and Services
MaxCyte is the trusted provider of high-performance, cell-engineering solutions and expertise.
Harness the power of the cell using one of our Scalable Transfection Systems or our custom Insourcing services.
Our Scalable Transfection Systems provide superior cell-engineering and seamlessly scale for efficient migration from early research to commercial manufacturing. Each system is tailored to meet the scalability and regulatory support needs for specific cell-engineering uses.
The MaxCyte STX® engineers from half a million (0.5 x 106) to 20 billion cells (2 x 1010) to support R&D from early-stage development through pre-clinical work.
The MaxCyte VLX® engineers from half a million (0.5 x 106 ) to 200 billion cells (2 x 1011) to support R&D through biomanufacturing.
The MaxCyte GT® has the scalability and established regulatory record for the development and manufacturing of clinical, cell and gene therapies.
ALL OUR SCALABLE TRANSFECTION SYSTEMS ARE:
Based on Flow Electroporation™ Technology with seamless scalability
Closed, computer-controlled instruments that are cGMP-compliant, ISO-certified and CE-marked
Supported by FDA master file, offering a clear regulatory pathway
To read more click here.
Any Cell. Any Molecule. Any Scale.®
Our delivery platform for cell engineering uses a non-viral, reproducible technology with high-level performance, flexibility and unmatched scalability.
MaxCyte’s cell engineering platform is based on Flow Electroporation™ Technology, a universal transfection technology capable of high-performance delivery of virtually any molecule, to any cell, at any scale. It has the unique ability to transfect primary cells, stem cells and cell lines with minimal cell disturbance and transfection efficiencies routinely >90% for a variety of cell types – rates that exceed those of other transfection methods. Flow Electroporation Technology is an inherently safe technology with a clear regulatory pathway that provides scientists with the freedom to use the most physiologically relevant system facilitating the identification, development and manufacturing of cell therapies, biotherapeutics and small molecule candidates of the highest quality. To read more please click here.
President and Chief Executive Officer
Mr. Doerfler has more than 35 years of experience in the discovery, development, commercialization and international financing of biotechnology products and companies. He was a founder of MaxCyte in July 1998. Previously, Mr. Doerfler was President, Chief Executive Officer and a director of Immunicon Corporation, a cell-based therapy and diagnostics company. He also held various executive positions with Life Technologies, Inc. that included leading its global businesses, mergers and acquisitions and its IPO. Mr. Doerfler plays an active role as a life sciences industry advocate, serving as Chair Emeritus of the Maryland Tech Council and on the Executive Committees of the Alliance for Regenerative Medicine and the Biotechnology Innovation Organization. Mr. Doerfler received his BS in finance from the University of Baltimore School of Business, and holds a certificate in Industrial Relations.
Chief Financial Officer
Mr. Holtz serves as MaxCyte’s Chief Financial Officer (CFO), having joined the Company in 2005. Previously, he has been CFO of both public and private companies and has raised more than $100 million in debt and equity capital. He also had previous experience with Ernst & Young LLP’s Financial Advisory Services Group. He earned an MBA in finance from the University of Maryland, a BS in mathematics from the University of Wisconsin and is a Certified Public Accountant.
Debra K. Bowes
Executive Vice President, Business and Strategic Development
Ms. Bowes has more than 25 years of experience in corporate strategy, licensing and in the creation of partnerships to advance the development and commercialization of biopharmaceutical products, with a main emphasis in oncology. Before joining MaxCyte in 2016, Ms. Bowes was Interim President and Chief Executive Officer of CapGenesis Pharma, in Bethesda, MD. Previously, she served as President and Founder of Chevy Chase BioPartners, LLC, a strategic planning consultancy, as well as in leadership positions at CBLI Pharmaceuticals, MedImmune, Amylin Pharmaceuticals, Pfizer, Ligand Pharmaceuticals, Centocor and Hybritech. She has also served as national president of Women In Bio. Ms. Bowes holds a Master’s Degree from Johns Hopkins University, and has a BS in cell biology from the University of Cincinnati.
Executive Vice President, Global Marketing
Mr. Calvin is a 25-year veteran within the diagnostics, drug development and biotechnology industries. In his role as MaxCyte’s EVP of Global Marketing, he is responsible for leading the Company’s marketing function to define product strategy and drive growth of its drug discovery and cell therapy business. Mr. Calvin was most recently Co-founder and President of AsedaSciences, a company with an integrated technology platform to predict in vivo toxicity risk in early-stage drug discovery. Previously, he has held various leadership positions at companies ranging from large corporations to start-ups, such as Accuvein, Beckman Coulter, Qiagen, Digene, AGENIX, and Abbott Laboratories. He has a Bachelor’s degree from Curtin Institute of Technology in Perth, Western Australia.
Thomas M. Ross
Executive Vice President, Global Sales
Mr. Ross serves as MaxCyte’s Executive Vice President of Global Sales, having joined the Company in 2014. Mr. Ross has extensive experience in all elements of commercial operations and has more than 25 years of successful sales and marketing leadership in the Life Science and Clinical Diagnostics markets. Most recently, Mr. Ross was Senior Vice President of Commercial Operations at OpGen®. Mr. Ross also served as Chief Commercial Officer at Predictive BioScience and Vice President of North America Medical Diagnostics Sales at Qiagen/Digene Corporation. Prior to working at Digene Corporation, he held several senior leadership roles in Manufacturing Operations at Life Technologies, Inc. and Cambrex. Mr. Ross has a Bachelor’s of Business Administration from The Citadel.
James Brady, PhD
Vice President, Technical Applications and Customer Support
Dr. Brady is Vice President of Technical Applications and Customer Support at MaxCyte, Inc. Prior to joining MaxCyte in 2004, Dr. Brady was a Senior Scientist at Genetic Therapy, Inc., a Novartis subsidiary, where he worked on lentiviral-based gene therapy treatments for ocular disorders. Previously, he worked at MetaMorphix, Inc. as a Group Leader in the Company’s Transgenic Livestock program, and was a postdoctoral fellow at the National Eye Institute of the National Institutes of Health. Dr. Brady received a Bachelor of Science degree in biology from the College of William and Mary, a Ph.D. in genetics from Indiana University and an MBA from Johns Hopkins University.
Vice President, Quality and Technical Operations
Mr. Kuo currently serves as MaxCyte’s Vice President of Quality and Technical Operations, having joined the Company in 2017. He has more than 20 years of biopharmaceutical and academic experience in developing cell, gene and regenerative medicine therapies. Mr. Kuo has established and directed numerous GMP manufacturing, quality assurance and analytical testing operations as well as provided oversight of global contract manufacturing and development organizations (CDMOs) and contract testing laboratories (CTLs). Prior to joining MaxCyte, Mr. Kuo served as Senior Director of Quality Assurance at Mesoblast, where he supported multiple global Phase III clinical studies. Previously, he held various leadership positions at BloodWorks Northwest, Cryo-Cell International, Aesculap Implant Systems and Amgen, providing oversight of process development, translational scale up, technology transfer and analytical testing. Mr. Kuo received his BS degrees in Medical Technology and Microbiology as well as his Biomedical Regulatory Affairs Certificate from the University of Washington.
Vice President, Legal
Mr. Masoud brings to MaxCyte 12 years of experience as an attorney and general counsel in the biotech industry. He has served as Assistant General Counsel and Corporate Secretary for Wellstat Management Company; co-founding partner of Rossi/Masoud LLC, a specialized law firm for the biotech, pharmaceutical and IT sectors; and Corporate Attorney at Human Genome Sciences, Inc. Mr. Masoud managed the legal team on the launch of two FDA-approved drugs while at Wellstat. At Human Genome Sciences, he assisted with FDA compliance for the product launch of Benlysta®, negotiated and executed more than 1,000 clinical trial agreements, negotiated licensing deals valued at over $300 million, and assisted the company with raising financing through bond and secondary stock offerings in excess of $800 million. A member of the Maryland State Bar, Mr. Masoud holds a JD from Michigan State University College of Law, and a BS in Cell & Molecular Biology Genetics from the University of Maryland.
22 Firstfield Road, Suite 110
Gaithersburg, MD 20878
Tel: (301) 944-1700
Fax :(301) 944-1703
email: [email protected]
BioHub at Alderley Park
MaxCyte has appointed Panmure Gordon to act as nominated adviser and broker to the Company for the purposes of the AIM Rules for Companies.
One New Change
London, EC4M 9AF